Epithelial V-Like Antigen Mediates Efficacy of Anti-Alpha4 Integrin Treatment in a Mouse Model of Multiple Sclerosis

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Wright, Erik ^a   Rahgozar, Kusha ^a   Hallworth, Nicholas ^c   Lanker, Stefan ^c   Carrithers, Michael D ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b Neurology Service   (United States)

^c BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; ALPHA4 INTEGRIN ANTIBODY; ANTIGEN; AUTOANTIBODY; CD19 ANTIGEN; COMPLEMENT; COMPLEMENT COMPONENT C3D RECEPTOR; EPITHELIAL V LIKE ANTIGEN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ALLERGIC GLOMERULONEPHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL COUNT; CELL HETEROGENEITY; CELL INFILTRATION; CELL MATURATION; CELL STRUCTURE; CHOROID PLEXUS; COMPLEMENT DEPOSITION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; EPITHELIUM CELL; FLOW CYTOMETRY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; TUMOR INVASION; WILD TYPE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; B-LYMPHOCYTES; CELL ADHESION MOLECULES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENE DELETION; GENE EXPRESSION; HUMANS; IMMUNIZATION; INTEGRIN ALPHA4; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MULTIPLE SCLEROSIS; SPINAL CORD;

EID: 84881326554     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070954     Document Type: Article

References (24)

1. Carrithers MD, (2012) Current immunotherapy of multiple sclerosis and future challenges: relevance of immune-mediated repair. Curr Pharm Biotechnol 13: 1409-1417.
2. Prosperini L, Gianni C, Barletta V, Mancinelli C, Fubelli F, et al. (2012) Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis. J Neurol Sci 323: 104-112.
3. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, et al. (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356: 63-66.
4. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899-910.
5. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, et al. (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366: 1870-1880.
6. Carrithers MD, Visintin I, Kang SJ, Janeway CA Jr, (2000) Differential adhesion molecule requirements for immune surveillance and inflammatory recruitment. Brain 123 (Pt 6): 1092-1101.
7. Carrithers MD, Visintin I, Viret C, Janeway CS Jr, (2002) Role of genetic background in P selectin-dependent immune surveillance of the central nervous system. J Neuroimmunol 129: 51-57.
8. Chatterjee G, Carrithers LM, Carrithers MD, (2008) Epithelial V-like antigen regulates permeability of the blood-CSF barrier. Biochem Biophys Res Commun 372: 412-417.
9. Wojcik E, Carrithers LM, Carrithers MD, (2011) Characterization of epithelial V-like antigen in human choroid plexus epithelial cells: potential role in CNS immune surveillance. Neurosci Lett 495: 115-120.
10. Guttinger M, Sutti F, Panigada M, Porcellini S, Merati B, et al. (1998) Epithelial V-like antigen (EVA), a novel member of the immunoglobulin superfamily, expressed in embryonic epithelia with a potential role as homotypic adhesion molecule in thymus histogenesis. J Cell Biol 141: 1061-1071.
11. Tang T, Li L, Tang J, Li Y, Lin WY, et al. (2010) A mouse knockout library for secreted and transmembrane proteins. Nat Biotechnol 28: 749-755.
12. Franciotta D, Salvetti M, Lolli F, Serafini B, Aloisi F, (2008) B cells and multiple sclerosis. Lancet Neurol 7: 852-858.
13. Sindhava VJ, Bondada S, (2012) Multiple regulatory mechanisms control B-1 B cell activation. Front Immunol 3: 372.
14. Yang Y, Ghosn EE, Cole LE, Obukhanych TV, Sadate-Ngatchou P, et al. (2012) Antigen-specific memory in B-1a and its relationship to natural immunity. Proc Natl Acad Sci U S A 109: 5388-5393.
15. Duan B, Morel L, (2006) Role of B-1a cells in autoimmunity. Autoimmun Rev 5: 403-408.
16. Finn WG, Singleton TP, Schnitzer B, Ross CW, Stoolman LM, (2001) Adhesion molecule expression in CD5-negative/CD10-negative chronic B-cell leukemias: comparison with non-Hodgkin's lymphomas and CD5-positive B-cell chronic lymphocytic leukemia. Hum Pathol 32: 66-73.
17. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, et al. (2007) Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130: 1089-1104.
18. Seidi OA, Semra YK, Sharief MK, (2002) Expression of CD5 on B lymphocytes correlates with disease activity in patients with multiple sclerosis. J Neuroimmunol 133: 205-210.
19. Mix E, Olsson T, Correale J, Baig S, Kostulas V, et al. (1990) B cells expressing CD5 are increased in cerebrospinal fluid of patients with multiple sclerosis. Clin Exp Immunol 79: 21-27.
20. Atwood WJ, Amemiya K, Traub R, Harms J, Major EO, (1992) Interaction of the human polyomavirus, JCV, with human B-lymphocytes. Virology 190: 716-723.
21. Planas R, Jelcic I, Schippling S, Martin R, Sospedra M, (2012) Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis. Eur J Immunol 42: 790-798.
22. Ransohoff RM, (2005) Natalizumab and PML. Nat Neurosci 8: 1275.
23. Kleiter I, Hellwig K, Berthele A, Kumpfel T, Linker RA, et al. (2012) Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 69: 239-245.
24. Palace J, Leite MI, Nairne A, Vincent A, (2010) Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol 67: 1016-1017.